Cochrane · systematic review · CD005441
Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C
Hauser, G, Awad, T, Brok, J, et al. · Cochrane Database of Systematic Reviews · 2014 · Cochrane Library
Hepato-BiliaryAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 1 · 33.3%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Peginterferon plus ribavirin versus non‐pegylated interferon plus ribavirin for chronic hepatitis C
Population: patients with chronic hepatitis C.
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Liver‐related morbidity plus all‐cause mortality Peginterferon plus ribavirin vs non‐pegylated interferon plus ribavirin | OR 1.14 [0.38, 3.42] | 1789 participants | Low Downgraded: imprecision, indirectness |
Adverse events leading to treatment discontinuation Peginterferon plus ribavirin vs non‐pegylated interferon plus ribavirin | RR 0.86 [0.68, 1.09] | 15 studies · 4571 participants | Low Downgraded: risk of bias, imprecision, inconsistency, indirectness |
Sustained virological response Peginterferon plus ribavirin vs non‐pegylated interferon plus ribavirin | RR 1.39 [1.25, 1.56] | 27 studies · 6104 participants | Very low Downgraded: risk of bias, imprecision, inconsistency, indirectness |